The occurrence of demyelination in patients receiving anti-TNFa treatment, as happened in our patients, could be either attributed to the unmasking of a latent preexisting MS, to the emergence of new demyelinating episode (either MS or MS like), or finally to incidental coexistence of the two disorders [18]. This evidence concerns the gene TNF and myeloid sarcoma.